1Department of Pathology, Faculty of Medicine, Suez Canal University, El Sheikh Zayed, Egypt
2Department of Basic Sciences, College of Medicine, Suliman Al Rajhi University, Al Bukairiyah, Saudi Arabia
3Department of Anatomy, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
4Department of Basic Medical Sciences, College of Medicine, Dar Al Uloom University, Riyadh, Saudi Arabia
5Department of Clinical Sciences, Suliman Al Rajhi University, Bukayriah, Saudi Arabia
6Department of Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
7Department of Pathology, College of Medicine, Jouf University, Al-Jawf, Saudi Arabia
© 2023 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
All procedures performed in the current study were approved by the Institutional Ethics Review Board of Suez Canal University (4687-5/12/2021) in accordance with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the study. A copy of the written consent is available for review by the Editor-in-Chief of the journal.
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Code Availability
Not applicable.
Author Contributions
Conceptualization: WAH. Data curation: AKE, NN, MEA, HL. Methodology: WAH, MEA, RIA. Project administration: WAH. Resources: WAH, NN, RIA. Supervision: WAH. Validation: WAH, RIA, NN. Visualization: HL, MEA, AKE. Writing—original draft: WAH, NN, RIA, MEA. Writing—review & editing: HL, AKE. Approval of final manuscript: all authors.
Conflicts of Interest
The authors declare that they have no potential conflicts of interest.
Funding Statement
No funding to declare.
Group | No. of cases | TAN (median) | TAL (median) | NLR |
---|---|---|---|---|
Grading: Low | ||||
Non-invasive neoplasms | 12 | 5.5 | 13.5 | 0.6 |
Non–muscle-invasive neoplasms | 18 | 8.0 | 41.0 | 0.8 |
Muscle-invasive neoplasms | 12 | 4.0 | 35.5 | 1.7 |
Grading: High | ||||
Non-invasive neoplasms | 24 | 11.5 | 12.5 | 0.5 |
Non–muscle-invasive neoplasms | 20 | 17.5 | 28.5 | 1.2 |
Muscle-invasive neoplasms | 20 | 30.0 | 25.5 | 0.9 |
Group | TAN | TAL | NLR |
---|---|---|---|
Grading: Low | |||
Non-invasive neoplasms vs. non–muscle-invasive neoplasms | .851 | .007 | .152 |
Non–muscle-invasive neoplasms vs. muscle-invasive neoplasms | .550 | .315 | > .999 |
Non-invasive neoplasms vs. muscle-invasive neoplasms | .460 | .052 | .128 |
Grading: High | |||
Non-invasive neoplasms vs. non–muscle-invasive neoplasms | .570 | .013 | .232 |
Non–muscle-invasive neoplasms vs. muscle-invasive neoplasms | .053 | .913 | .041 |
Non-invasive neoplasms vs. muscle-invasive neoplasms | .012 | .005 | .792 |
Group | CD4+ T lymphocytes | CD8+ T lymphocytes |
---|---|---|
Grading: Low | ||
Non-invasive neoplasms vs. non–muscle-invasive neoplasms | .552 | .045 |
Non–muscle-invasive neoplasms vs. muscle-invasive neoplasms | .471 | .052 |
Non-invasive neoplasms vs. muscle-invasive neoplasms | .932 | .812 |
Grading: High | ||
Non-invasive neoplasms vs. non–muscle-invasive neoplasms | .864 | .220 |
Non–muscle-invasive neoplasms vs. muscle-invasive neoplasms | .425 | .821 |
Non-invasive neoplasms vs. muscle-invasive neoplasms | .791 | .335 |
NLR, neutrophil-to-lymphocyte ratio; TAN, tumor-associated neutrophils; TAL, tumor-associated lymphocytes.
Significant at p < .05. NLR, neutrophil-to-lymphocyte ratio; TAN, tumor-associated neutrophils; TAL, tumor-associated lymphocytes.
Significant at p < .05.